The company's main business is pharmaceutical preparations, raw materials and intermediates, and it has formed a product pattern with obvious characteristics of cardiovascular drugs, antidepressants and antiviral drugs, which are refined and strong, serialized and developed on a large scale. Among them, ACE inhibitors, a cardiovascular drug, have the largest variety, the largest production and sales volume, and the world-leading technical level, enjoying the reputation of "Puli experts". The company has a sound management system, and all its products have passed the national GMP certification. It is one of the enterprises with the most international drug quality certification in China.
In June 2007, Nevirapine, the company's anti-AIDS drug, passed the US FDA certification with zero defects, becoming the first pharmaceutical company in China to obtain the certification, and obtained the pass for Huahai pharmaceutical products to enter the high-end markets in Europe and America, filling the gap in the export of China's pharmaceutical products to the United States, and setting up a proud monument in the history of China's pharmaceutical industry development.
On October 9th, 2006, the company was approved by the Leading Group for Enterprise Listing of Zhejiang Provincial People's Government in document [20065438+0] No.5. A joint-stock company established by the original shareholders of Zhejiang Huahai Pharmaceutical Group Co., Ltd. Chen Baohua, Zhou Minghua, thunis Science and Technology Innovation Investment Co., Ltd., Beijing Oriental Classic Business Consultant Co., Ltd., Zhejiang Yangmei International Petrochemical and Pharmaceutical Engineering Design Co., Ltd., Ningbo TEDA Import and Export Co., Ltd. and Shi Huilin was registered in Zhejiang Administration for Industry and Commerce on February 28, 2006, with 200 1. 65438 On October 28th, 2003, approved by China Securities Regulatory Commission, the company issued 35 million A shares to the public.